Seagen®

Corporate Sponsored Presentations

Oral/Poster Session Information

Session Time (CDT)/ Location	Abstract #/Title/Lead Author	Type/Session Category & Title
Friday, June 2, 2023		
Friday, June 2, 2023 2:45 PM – 5:45 PM	**4007 / Tucatinib SGNTUC-019** Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study Lead Author: **Y Nakamura**	**Oral Presentation** Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Saturday, June 3, 2023		
Saturday, June 3, 2023 8:00 AM – 11:00 AM	**4568 / Enfortumab Vedotin EV-103 Cohort K** Enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin-ineligible patients (pts) with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data Lead Author: **T Friedlander**	**Poster Presentation** Genitourinary Cancer—Kidney and Bladder
Saturday, June 3, 2023 8:00 AM – 11:00 AM	**4595 / Enfortumab Vedotin EV-103 Cohort H** Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H Lead Author: **T Flaig**	**Poster Presentation** Genitourinary Cancer—Kidney and Bladder
Saturday, June 3, 2023 8:00 AM – 11:00 AM	**4596 / Enfortumab Vedotin EV-104** A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104) Lead Author: **A Kamat**	**Poster Presentation** Genitourinary Cancer—Kidney and Bladder
Saturday, June 3, 2023 8:00 AM – 11:00 AM	**TPS4601/ Enfortumab Vedotin EV-303** KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC) Lead Author: **A Necchi**	**Poster Presentation** Genitourinary Cancer—Kidney and Bladder
Saturday, June 3, 2023 8:00 AM – 11:00 AM	**3024 / SGN-B6A SGNB6A-001** SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001) Lead Author: **A Hollebecque**	**Poster Presentation** Developmental Therapeutics/Molecularly Targeted Agents and Tumor Biology
Saturday, June 3, 2023 1:15 PM – 4:15 PM	**TPS9597 / SGN-BB228 SGNBB228-001** Phase 1 study of SGN-BB228, an investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific, in patients with advanced melanoma and other solid tumors (SGNBB228-001: trial in progress) Lead Author: **J Henry**	**Poster Presentation** Melanoma/Skin Cancers
Sunday, June 4, 2023		
Sunday, June 4, 2023 8:00 AM – 11:00 AM	**1051 / Tucatinib HEOR** Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer Lead Author: **C Anders**	**Poster Presentation** Breast Cancer—Metastatic
Sunday, June 4, 2023 8:00 AM – 11:00 AM	**TPS1115 / Tucatinib SGNTUC-028** HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (trial in progress) Lead Author: **E Hamilton**	**Poster Presentation** Breast Cancer—Metastatic

Monday, June 5, 2023		
Monday, June 5, 2023 8:00 AM – 11:00 AM	**3528 / Tucatinib SGNTUC-017** HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS Lead Author: **J Strickler**	**Poster Presentation** Gastrointestinal Cancer—Colorectal and Anal
Monday, June 5, 2023 8:00 AM – 11:00 AM	**TPS3631 / Tucatinib SGNTUC-029** MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer (trial in progress) Lead Author: **T Bekaii-Saab**	**Poster Presentation** Gastrointestinal Cancer—Colorectal and Anal
Monday, June 5, 2023 11:30 AM – 2:30 PM	**4505 / Enfortumab Vedotin EV-103 Dose Escalation/Cohort A** Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up Lead Author: **S Gupta**	**Oral Presentation** Oral Abstract Session Genitourinary Cancer—Kidney and Bladder
Monday, June 5, 2023 1:15 PM – 4:15 PM	**6017 / Enfortumab Vedotin EV-202** Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202 Lead Author: **P Swiecicki**	**Poster Discussion** Poster Discussion Session—Head and Neck Cancer

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Seagen®

IST Presentations

Oral/Poster Session Information

Session Time (CDT)	Abstract #/Title/Lead Author	Type/Session Category & Title
Saturday, June 3, 2023 8:00 AM – 11:00 AM	**4566 / Disitamab vedotin RC48-C014** Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: an open-label phase 1b/2 study Lead Author: **X Sheng**	**Poster Presentation** Genitourinary Cancer—Kidney and Bladder
Sunday, June 4, 2023 8:00 AM – 11:00 AM	**TPS1116 / Tucatinib UCLA B-13** UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer (TiP) Lead Author: **N McAndrew**	**Poster Presentation** Breast Cancer—Metastatic

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.